AbbVie has a solid medium-term growth plan and the means to accomplish it. Acquisitions and licensing deals could make for unexpected upsides. Still, its shares aren't priced inexpensively at the ...

AbbVie presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making ...

Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $220 from $212 and keeps an Overweight rating on the shares. The firm is increasing its Skyrizi and ...

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to ...

The West Virginia case is seen as a win for drugmakers following a U.S. Supreme Court setback earlier in the month, but the ...

On December 18, a recent SEC filing unveiled that Kevin K Buckbee, SVP at AbbVie ABBV made an insider sell. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other dividend stocks. Generating income has consistently been a primary goal for investors.

Middle East, Africa and Russia Rheumatology Grand Educational medical summit “MERGE” was launched by AbbVie, the global biopharmaceutical company, this summit is in its second edition to raise the ...

AbbVie has completed a hat trick of phase 3 wins for its Parkinson’s disease prospect tavapadon, teeing the drugmaker up to file for FDA approval in 2025. The Big Pharma acquired the once-daily ...

This marks AbbVie’s second Emotional Impact Report. The first, which didn’t break down CLL patients by race or ethnicity, arrived in 2022 and highlighted the viewpoints of doctors and ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out daily tasks such as eating and walking, months after the drugmaker ...

Gifting allows recipients to access the article for free. AbbVie is continuing its dealmaking spree with a $200 million acquisition of a biotech firm that spun out of pharmaceutical giant Roche.